Premium
Ocrelizumab Concentration Is a Good Predictor of SARS‐CoV ‐2 Vaccination Response in Patients with Multiple Sclerosis
Author(s) -
Kempen Zoé L. E.,
Hogenboom Laura,
Toorop Alyssa A.,
Steenhuis Maurice,
Stalman Eileen W.,
Kummer Laura Y. L.,
Dam Koos P. J.,
Bloem Karien,
Brinke Anja,
Ham S. Marieke,
Kuijpers Taco W.,
Wolbink Gerrit J.,
Loeff Floris C.,
Wieske Luuk,
Eftimov Filip,
Rispens Theo,
Strijbis Eva M. M.,
Killestein Joep
Publication year - 2023
Publication title -
annals of neurology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 4.764
H-Index - 296
eISSN - 1531-8249
pISSN - 0364-5134
DOI - 10.1002/ana.26534
Subject(s) - ocrelizumab , medicine , vaccination , multiple sclerosis , immunology , monoclonal antibody , cd20 , titer , antibody , rituximab
Ocrelizumab, an anti‐CD20 monoclonal antibody, counteracts induction of humoral immune responses after severe acute respiratory syndrome‐coronavirus 2 (SARS‐CoV‐2) vaccinations in patients with multiple sclerosis (MS). We aimed to assess if serum ocrelizumab concentration measured at the time of vaccination could predict the humoral response after SARS‐CoV‐2 vaccination. In 52 patients with MS, we found ocrelizumab concentration at the time of vaccination to be a good predictor for SARS‐CoV‐2 IgG anti‐RBD titers after vaccination (comparable to B‐cell count). As the course of ocrelizumab concentration may be predicted using pharmacokinetic models, this may be a superior biomarker to guide optimal timing for vaccinations in B‐cell depleted patients with MS. ANN NEUROL 2023;93:103–108